DE69431911T2 - Purin-nukleosid phosphorylase gentherapie der menschlichen bösartigen krankheiten - Google Patents

Purin-nukleosid phosphorylase gentherapie der menschlichen bösartigen krankheiten

Info

Publication number
DE69431911T2
DE69431911T2 DE69431911T DE69431911T DE69431911T2 DE 69431911 T2 DE69431911 T2 DE 69431911T2 DE 69431911 T DE69431911 T DE 69431911T DE 69431911 T DE69431911 T DE 69431911T DE 69431911 T2 DE69431911 T2 DE 69431911T2
Authority
DE
Germany
Prior art keywords
vicious
diseases
human
purine nucleoside
nucleoside phosphorylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431911T
Other languages
English (en)
Other versions
DE69431911D1 (de
Inventor
J Sorscher
B Parker
L Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOUTHERN RES INST BIRMINGHAM
UAB Research Foundation
Southern Research Institute
Original Assignee
SOUTHERN RES INST BIRMINGHAM
UAB Research Foundation
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOUTHERN RES INST BIRMINGHAM, UAB Research Foundation, Southern Research Institute filed Critical SOUTHERN RES INST BIRMINGHAM
Application granted granted Critical
Publication of DE69431911D1 publication Critical patent/DE69431911D1/de
Publication of DE69431911T2 publication Critical patent/DE69431911T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69431911T 1993-09-14 1994-09-14 Purin-nukleosid phosphorylase gentherapie der menschlichen bösartigen krankheiten Expired - Lifetime DE69431911T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/122,321 US5552311A (en) 1993-09-14 1993-09-14 Purine nucleoside phosphorylase gene therapy for human malignancy
PCT/US1994/010130 WO1995007718A2 (en) 1993-09-14 1994-09-14 Purine nucleoside phosphorylase gene therapy for human malignancy

Publications (2)

Publication Number Publication Date
DE69431911D1 DE69431911D1 (de) 2003-01-30
DE69431911T2 true DE69431911T2 (de) 2003-05-28

Family

ID=22402034

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431911T Expired - Lifetime DE69431911T2 (de) 1993-09-14 1994-09-14 Purin-nukleosid phosphorylase gentherapie der menschlichen bösartigen krankheiten

Country Status (6)

Country Link
US (1) US5552311A (de)
EP (1) EP0715523B1 (de)
JP (1) JP3874420B2 (de)
CA (1) CA2171618C (de)
DE (1) DE69431911T2 (de)
WO (1) WO1995007718A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017896A (en) * 1993-09-14 2000-01-25 University Of Alabama Research Foundation And Southern Research Institute Purine nucleoside phosphorylase gene therapy for human malignancy
US6491905B1 (en) * 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
CA2222574A1 (en) * 1995-06-07 1996-12-19 Yale University Oral delivery of adeno-associated viral vectors
KR100449181B1 (ko) * 1995-06-15 2005-01-24 크루셀 홀란드 비.브이. 유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
WO2003002746A2 (en) * 2001-06-29 2003-01-09 Novartis Ag Perv screening method and use thereof
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
AU2003211103A1 (en) * 2002-02-13 2003-09-04 Northeastern University Intracellular delivery of therapeutic agents
DK1497438T3 (da) * 2002-04-25 2010-01-04 Crucell Holland Bv Midler og fremgangsmåder til fremstilling af adenovirusvektorer
WO2004027029A2 (en) * 2002-09-19 2004-04-01 Ximerex, Inc. Growth of foreign cells in fetal animals facilitated by conditional and selective destruction of native host cells
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
JP5002851B2 (ja) * 2005-01-20 2012-08-15 独立行政法人理化学研究所 イミダゾピリジン誘導体
WO2008082440A2 (en) * 2006-08-25 2008-07-10 Emory University Fluorescent nucleoside analogues
DE102007008890A1 (de) 2007-02-21 2008-09-04 Universität Hamburg Nukleinsäure, die für eine pflanzliche Adenosin-Nukleosidase kodiert
KR20110074847A (ko) * 2008-08-15 2011-07-04 더 유에이비 리서치 파운데이션 뉴클레오시드 프로드럭의 효소 활성자로서의 퓨린 뉴클레오시드 인산화효소
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
AP3584A (en) 2010-09-22 2016-02-09 Alios Biopharma Inc Substituted nucleotide analogs
PL2797613T3 (pl) 2011-10-27 2020-06-15 Wellstat Ophthalmics Corporation Wektory kodujące pręcikowy czynnik żywotności czopków
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE411392B (sv) * 1977-12-09 1979-12-17 Inst Mikrovagsteknik Vid Tekni Metanordning for kapacitiv bestemning av det inbordes leget hos tva relativt varandra rorliga delar
JPS55139416A (en) * 1979-04-17 1980-10-31 Mitsubishi Chem Ind Ltd Production of urea-4c saturated aliphatic aldehyde condensate powder
JPS62129749A (ja) * 1985-11-29 1987-06-12 Toyota Motor Corp 雨センサ
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
JP4094563B2 (ja) * 2004-02-16 2008-06-04 株式会社エース電研 遊技機

Also Published As

Publication number Publication date
WO1995007718A3 (en) 1995-04-13
EP0715523A1 (de) 1996-06-12
US5552311A (en) 1996-09-03
EP0715523B1 (de) 2002-12-18
WO1995007718A2 (en) 1995-03-23
CA2171618C (en) 2007-12-11
JP3874420B2 (ja) 2007-01-31
DE69431911D1 (de) 2003-01-30
CA2171618A1 (en) 1995-03-23
JPH09502612A (ja) 1997-03-18

Similar Documents

Publication Publication Date Title
DE69431911T2 (de) Purin-nukleosid phosphorylase gentherapie der menschlichen bösartigen krankheiten
KR910002326A (ko) 치료용 뉴클레오시드
DE19575021I2 (de) Therapeutische Nucleoside
ATE181917T1 (de) Therapeutische nukleoside
ATE138660T1 (de) Therapeutische nukleoside
PL322464A1 (en) Stimulation of biuological tissue by use of optical energy
NZ269653A (en) Treatment of protein kinase c-related diseases by gene therapy
DK191688A (da) Terapeutiske nucleosider
PL336760A1 (en) Treatment of skin diseases
PL336579A1 (en) Treatment of diseases associated with cytokinins
DK406689A (da) Terapeutiske nucleosider
NO981564D0 (no) Terapeutisk administrering av hemoglobin ved hjertestans
FI942400A0 (fi) Lääkeaine hermosairauksia vastaan
NO953349D0 (no) Kombinasjonsterapi av human cancer med cisplatin/tamoxifen
PT876146E (pt) Analogos de nucleosidos em terapia de combinacao de infeccoes por herpes simplex
MC1914A1 (fr) Nucleosides therapeutiques
PT100435A (pt) Nucleosidos terapeuticos
IT1210305B (it) Massaggiatore per corpo umano
ZA936136B (en) Treatment of skin diseases
GB8806116D0 (en) Treatment of skin diseases
DK725088A (da) Terapeutiske nucleosider
ITRM920721A0 (it) Perfezionamento dei manubri per ginnastica terapeutica
GB8825464D0 (en) Electro therapy chair for treatment of various dermatological & rheumatological diseases
GB9026620D0 (en) Treatment of lung diseases
SI0876146T1 (en) Nucleoside analogs in combination therapy of herpes simplex infections

Legal Events

Date Code Title Description
8364 No opposition during term of opposition